Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.31 |
| ▸ | F7 | P08709 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
| ▸ | F3 | P13726 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP2 | P08253 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | MMP12 | P39900 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129830 | 0.75 | PARP10 (0.36) | F7PARP1F3PARP10 | |
| SCHEMBL30279445 | 0.75 | PARP10 (0.36) | F7PARP1F3PARP10 | |
| SCHEMBL23978990 | 0.67 | PARP10 (0.36) | MRGPRX4F7PARP1F3PARP10 | |
| SCHEMBL10129821 | 0.65 | ACHE (0.50) | F7PARP1F3PARP10 | |
| SCHEMBL30402278 | 0.65 | ACHE (0.50) | F7PARP1F3PARP10 | |
| SCHEMBL23978726 | 0.62 | PARP1 (0.41) | F7PARP1F3PARP10 | |
| SCHEMBL30401909 | 0.62 | PARP1 (0.41) | F7PARP1F3PARP10 | |
| SCHEMBL24886285 | 0.61 | PARP10 (0.56) | F7PARP1F3PARP10 | |
| SCHEMBL14842620 | 0.60 | ACHE (0.54) | F7PARP1F3PARP10 | |
| SCHEMBL14844702 | 0.59 | NCOA1 (0.41) | F7PARP1F3PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | MRGPRX4 1817/4885F7 2457/4885PARP1 1110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.